Study Stopped
Due to COVID the enrollment into the study was delayed. Sponsor chose to collect clinical data via alternative methods.
Due to COVID the enrollment into the study was delayed. Sponsor chose to collect clinical data via alternative methods.
Sponsor study identifier
observational
119
4 countries
5
Study Start
January 22, 2020
Actual (reported)Primary Completion
December 8, 2022
Actual (reported)Study Completion
July 12, 2023
Actual (reported)WRIGHT FOOT \& ANKLE POST-MARKET OBSERVATIONAL STUDY, Multi-Year, Multi-Site, Multi-Device, Post-Market Observational Study, 10 sites, a minimum of 40 patients per device
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 12, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 21, 2019
Actual (reported)October 8, 2019
Actual (reported)January 22, 2020
Actual (reported)December 8, 2022
Actual (reported)July 12, 2023
Actual (reported)January 14, 2025
Actual (reported)EuroQol (EQ-5D-5L).
Comparing the changes in patient-reported pain and social interaction for quality of life from pre-op through post-operatively, assessed by the EuroQol (EQ-5D-5L). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. Health utility values generated from the EQ-5D generally range from 0 (death) to 1 (perfect health). But health utility values less than 0 are possible, and represent health states considered worse than death. The EQ VAS records the patient's self-rated health on a VAS (0-100), where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.
1 year
Foot and Ankle Ability Measure (FAAM)
1 year
Safety Assessment
1 year
Surgeon Survey
1 year
Patient Survey
1 year
The study subjects included are those treated with one or more approved or cleared Wright Medical products included in this study.
Wright devices used in foot and ankle procedures
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The Instructions for Use (IFU) for each individual product can be found at http://www.wright.com/prescribing-use-3.
Mercer-Bucks Orthopaedics
Hamilton, New Jersey, 08691, United States
OrthoCarolina
Charlotte, North Carolina, 28207, United States
CHRU Tours, Hôpital Trousseau
Tours, 37044, France
Hessingpark Clinic
Augsburg, Germany
Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Oswestry, Shropshire, United Kingdom
Rebecca Gibson
Stryker Trauma and Extremities
119 participants (actual enrollment reported by the registry).
First Submitted
August 21, 2019
First Posted
October 8, 2019
Study Start
January 22, 2020
Actual (reported)A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Contact the study team to confirm eligibility.
Primary Completion
December 8, 2022
Actual (reported)Study Completion
July 12, 2023
Actual (reported)Last Updated
January 14, 2025
Results First Posted
January 14, 2025
Record last verified: 2025-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: